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The Human Immunodeficiency Virus (HIV) coreceptor
switch, which entails the change in preferential coreceptor
usage of the virus for CCR5 to CXCR4 in ~50% of all HIV
subtype B infected patients, is an important determinant
in the pathogenesis of HIV infection. However, the mech-
anisms underlying this switch are poorly understood, and
prognostic markers for this switch are unknown. Here, we
describe the upregulation of the novel adipocytokine vis-
fatin (NAMPT) in monocytes of therapy-naïve HIV
patients, which is reversed during antiretroviral therapy.
Induction of visfatin was observed both at the mRNA and
protein level and was mirrored by an increase in plasma
visfatin in therapy-naïve HIV patients. Visfatin expression
correlates with the viral load, and high visfatin expression
appears to be associated with the dominance of CXCR4-
using HIV in the plasma. We show that visfatin is capable
of selectively reducing the infectivity of CCR5-using
clones in primary cells (macrophages, resting PBMC) in
vitro, while at the same time remaining indifferent to or
even favouring infection by CXCR4-using virus. As such,
visfatin may play an important contributing role in the
development of the HIV coreceptor switch by mounting a
selective pressure against CCR5-using and in favour of
CXCR4-using viruses.
from Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts
Montpellier, France. 21-23 September 2009
Published: 24 September 2009
Retrovirology 2009, 6(Suppl 2):P88 doi:10.1186/1742-4690-6-S2-P88
<supplement> <title> <p>Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts</p> </title> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S2-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-6-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S2/P88
© 2009 Bergh et al; licensee BioMed Central Ltd. 